Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03085888 · ClinicalTrials.gov registry record
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
A clinical trial, sponsored by GRAIL.
- Completed
- Registry status
- 99,481
- Enrollment target
NCT03085888: Completed study, sponsored by GRAIL.
NCT03085888 is a clinical trial that has completed, run by GRAIL. The registered enrollment target is 99,481 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03085888 has completed, sponsored by GRAIL.
- COMPLETED
- Registry status
- 99,481 participants
- Enrollment target
Study Summary
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,481 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2024-04-01 |
What the finished NCT03085888 record still lists
NCT03085888 is an observational study that tracks outcomes without assigning an intervention. Its 99,481 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03085888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03085888 about?
NCT03085888 is a clinical study titled "The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types". GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malign...
What is the current status of trial NCT03085888?
This trial is currently completed. The enrollment target is 99,481 participants. The study started on 2017-02-28. Estimated completion is 2024-04-01.
Who is sponsoring clinical trial NCT03085888?
This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI